Centessa Pharmaceuticals plc (CNTA) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $39.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality.
Centessa Pharmaceuticals is a clinical-stage biotech developing OX2R agonists for narcolepsy (NT1/NT2) and idiopathic hypersomnia, with lead compound cleminorexton in Phase 2 trials. Eli Lilly announced a $38/share acquisition plus CVRs in March 2026, expected to close Q3 2026;... Read more
Sell if holding. Engine safety override at $39.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Score 4.1/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 86d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Centessa Pharmaceuticals plc
Latest news
- Wells Fargo Downgrades Centessa Pharmaceuticals to Equal-Weight, Raises Price Target to $42 — benzinga Apr 20, 2026 negative
- Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptc — benzinga Apr 3, 2026 neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHpipelineorexin program10-K Item 1A: 'A large proportion of our value may at any time reside in a limited number of our programs and/or developmental assets or product candidates, as we believe is currently the case in light of our focus on our orexin program.'
Material Events(8-K, last 90d)
- 2026-02-13Item 5.02LOWFormer CEO Saurabh Saha (stepped down Jan 1, 2026) entered Advisory Agreement ($376/hr) and Separation Agreement on Feb 9, 2026; equity vesting after Feb 2, 2026 forfeited. No new departure noted.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $39.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Prior stop was $39.31. Score 4.1/10, moderate confidence.
Take-profit target: $39.04 (-1.4% upside). Prior stop was $39.31. Stop-loss: $39.31.
Concentration risk — Pipeline: orexin program; Target reached (-2.1% upside); Quality below floor (1.6 < 4.0).
Centessa Pharmaceuticals plc trades at a P/E of N/A (forward -20.9). TrendMatrix value score: 4.0/10. Verdict: Sell.
19 analysts cover CNTA with a consensus score of 3.7/5. Average price target: $45.
What does Centessa Pharmaceuticals plc do?Centessa Pharmaceuticals is a clinical-stage biotech developing OX2R agonists for narcolepsy (NT1/NT2) and idiopathic...
Centessa Pharmaceuticals is a clinical-stage biotech developing OX2R agonists for narcolepsy (NT1/NT2) and idiopathic hypersomnia, with lead compound cleminorexton in Phase 2 trials. Eli Lilly announced a $38/share acquisition plus CVRs in March 2026, expected to close Q3 2026; the company has no product revenue.